Menu

Impact Events

More
Date Lead Company Event Type Approval Change Approval Likelihood
9/14/26 BioNTech (BNTX) gotistobart for Non-Small Cell Lung Cancer (NSCLC) Subscribers Only Subscribers Only Subscribers Only
9/14/26 Johnson & Johnson (JNJ) Rybrevant Faspro for Non-Small Cell Lung Cancer (NSCLC) Subscribers Only Subscribers Only Subscribers Only
9/13/26 Daiichi Sankyo (4568) Enhertu for Non-Small Cell Lung Cancer (NSCLC) Subscribers Only Subscribers Only Subscribers Only
9/13/26 Akeso (9926) Idafang for Non-Small Cell Lung Cancer (NSCLC) Subscribers Only Subscribers Only Subscribers Only
9/10/26 Ferring Pharmaceuticals Hernicore for Sciatica Subscribers Only Subscribers Only Subscribers Only

Upcoming Catalysts

More
Expected Date Range Lead Company Drug Expected Catalyst
07/31/2025 Subscribers Only Subscribers Only Regulatory - sNDA/sBLA Filing
09/30/2025 Subscribers Only Subscribers Only Trial Announcement - Trial Completion
10/28/2025 Subscribers Only Subscribers Only Company - Analyst/R&D Update
10/31/2025 Subscribers Only Subscribers Only Company - Analyst/R&D Update
11/11/2025 Subscribers Only Subscribers Only Company - Analyst/R&D Update